

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 November 2003 (06.11.2003)

PCT

(10) International Publication Number
WO 03/090777 A1

(51) International Patent Classification⁷: **A61K 38/22**,
38/55, A61P 3/00 // (A61K 38/55, 38:22) (A61K 38/22,
31:445)

(74) Agent: **PRINS, A., W.**; Nieuwe Parklaan 97, NL-2587 BN
Den Haag (NL).

(21) International Application Number: PCT/NL.03/00303

(22) International Filing Date: 24 April 2003 (24.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02076675.4 25 April 2002 (25.04.2002) EP
60/375,557 25 April 2002 (25.04.2002) US

(71) Applicants (*for all designated States except US*): **UNIVERSITEIT UTRECHT HOLDING B.V.** [NL/NL]; Jenalaan 18a, NL-3584 CK Utrecht (NL). **UMC UTRECHT HOLDING B.V.** [NL/NL]; Jenalaan 18a, NL-3584 CK Utrecht (NL).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **STROUS, Gerardus, Jacobus, Antonius, Maria** [NL/NL]; Gendershof 6, NL-4175 AP Haaften (NL). **VAN KERKHOF, Petrus, Johannes, Maria** [NL/NL]; Retstraat 19, NL-6658 DB Beneden Leeuwen (NL).

(81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATION THERAPY TO TREAT A CATABOLIC STATE IN A PATIENT

(57) Abstract: The invention relates to the field of proteins, more specifically to proteins that are located on the surface of cells. The invention amongst others provides a method for up-regulating the bio-availability of a cell surface receptor comprising decreasing both the uptake and/or degradation of said receptor and the extracellular cleaving of said receptor. The invention further provides pharmaceutical compositions for up-regulating the bio-availability of a GHR comprising a proteasome/ubiquitination inhibitor and an MMP inhibitor and the use of said pharmaceutical compositions for the manufacture of a medicament for increasing anabolic conditions in human patients suffering from a catabolic state and/or cachexia.



WO 03/090777 A1

Title: Combination therapy to treat a catabolic state in a patient.

The invention relates to the field of biology, more in particular to the field of medicine, more in particular to the treatment of a cachectic and/or a catabolic state in a patient caused by, for example, cancer, aids, severe burning uremia, Cushing's syndrome, neuromuscular disorders, immobility, and/or old age.

Growth hormone (GH) is essential for body growth in children. In adults, GH continues to stimulate many anabolic processes. The secretion of GH by the pituitary gland is pulsatile. For signal transduction, the presence of GH and GH receptors (GHR) is equally important. All body tissues contain the GHR. New insights have initiated new applications and a growing potential for GH replacement therapy in adults. In catabolic situations like cancer, aids, severe burning uremia, Cushing's syndrome, neuromuscular disorders and in persons that are bedridden, the activity of the GHR is decreased resulting in a loss of muscle tissue and skin proteins (wasting); the process of aging induces similar processes (reviewed in Mitch and Goldberg, 1996; Baumann, 2001).

The ubiquitin-system is involved in the degradation of the GHR (Strous and Govers, 1999; van Kerkhof et al., 2002). Selective degradation of many cytosolic proteins in eukaryotic cells is carried out by the ubiquitin system (Ciechanover and Schwartz, 2002). In this pathway, proteins are targeted for degradation by covalent ligation to ubiquitin. Ubiquitin-mediated degradation of regulatory proteins plays an important role in the control of numerous processes, including cell-cycle progression, signal transduction, transcriptional regulation, receptor down regulation, and endocytosis. The ubiquitin system has been implicated in immune response, development of the body, and programmed cell death. The specificity is guaranteed via a multitude of ubiquitin ligases (E3s), mostly multimodular protein complexes, which recognize target proteins and ligate ubiquitin moieties to the ϵ -NH₂-group of lysine residues (Hershko et al., 2000). In muscle wasting the activity

of the ubiquitin system is strongly increased, as reflected by increased levels of ubiquitin-conjugases, -ligases and proteasomes, while the synthesis of most other proteins is reduced (Mitch and Goldberg). The recognition that the system also regulates the residence time at the cell surface for receptors like for instance the GHR, opens new ways to control their activities.

Apart from gene expression and mRNA stability, the number of GHRs per cell depends on its synthesis and quality control in the endoplasmic reticulum, removal of the GHR from the cell surface by proteases (shedding) and endocytosis, and the efficiency of targeting to lysosomes. Our recent experiments have shown that the availability of GHR for signal transduction upon GH binding is largely determined by the rate of uptake. GHR uptake is via clathrin-mediated endocytosis like for most cell surface receptors, e.g. transferrin, epidermal growth factor, insulin (van Kerkhof et al., 2002). A special feature of the GHR is that the ubiquitin system is required for uptake. A short intracellular amino acid motif is identified as a target for the ubiquitin system (Strous and Govers, 1999). When this motif is altered or when the ubiquitin system is switched off, the GHR residence time at the cell surface is prolonged 2-3-fold. The same effect would be anticipated by proteasome inhibitors. Treatment with proteasome inhibitors and/or ubiquitination inhibitors would therefore be beneficial for patients suffering from a catabolic state.

Recent studies have addressed the mechanisms involved in GHR shedding: removal of the extracellular GH-binding domain is accomplished by a metalloprotease, identified as tumor necrosis factor (TNF)- α -converting enzyme (ADAM 17 or TACE) (Zhang et al., 2000). The activity of this enzyme is increased by phorbol esters, presumably through a pathway involving the protein kinase C α (Amit et al., 2001). Phorbol ester-induced GHR proteolysis in 3T3-F442A and CHO-cells expressing rabbit GHR was significantly reduced

by pretreatment with mitogen-activated protein (MAP) kinase inhibitors, suggesting involvement of the MAP kinase pathway (Takagi et al., 2001).

The present invention discloses that the ubiquitin/proteasome system is a negative regulator of this pathway. Thus, proteasome/ubiquitination inhibitors enhance the activity of TACE resulting in increased shedding of GHR from the cell membrane. As a consequence, the expected increase in residence time of GHR on the cell membrane, as a result of proteasome/ubiquitination inhibitors, is decreased by the enhanced activity of TACE. The net effect of proteasome/ubiquitination inhibitors on the treatment of a catabolic state in patients is therefore less than expected.

Thus, there is a need for pharmacological tools or medication that can both up-regulate the number of GHR and/or prolong the residence time of GHR on a cell surface, for example to make a patient responding better to hormonal therapy or to provide the cells of said patient with a higher sensitivity to an endogenous hormone or other ligand.

The present invention provides a method for up-regulating the bio-availability of a cell surface receptor, for example growth hormone receptor (GHR), comprising decreasing both the degradation and the extracellular cleaving of said receptor. This is achieved by combining the actions of a proteasome/ubiquitination inhibitor and an MMP inhibitor. Surprisingly, this combination shows a synergistic effect on the increase in amount and residence time of the GHR on the cell membrane. In a preferred embodiment of the invention, the uptake in the cell, also known as endocytosis, following ubiquitin-ligation, and degradation in the lysosomes induced by the proteasome-ubiquitin system of said GHR is decreased by an inhibitor of the proteasome/ubiquitination system, and at the same time the cleaving of said GHR on the outside of the cell membrane is decreased by an inhibitor of matrix metalloprotein. As a result, the number of available GHR on the cell membrane is increased and also the residence time of said GHR on the

membrane is prolonged. Therefore, in a preferred embodiment this invention provides a method for up-regulating the bio-availability of a cell surface receptor, for example growth hormone receptor (GHR), comprising decreasing both the degradation of said receptor by the proteasome/ubiquitination system and the cleaving of said receptor by a matrix metalloprotein (MMP) inhibitor, for example, a TACE inhibitor. Of course the increase in the amount and residence of said GHR on the cell surface is optimal if both said inhibitors are bio available in the body at the same time. Bio available means that the inhibitor is present in such chemical or physical form as to be capable of being utilized by a living organism.

Therefore, in a preferred embodiment of the invention, a proteasome inhibitor is provided in sufficient amount in conjunction with sufficient amounts of an MMP inhibitor. In conjunction herein meaning that said proteasome/ubiquitination inhibitor is used or applied before, during or after administration of a sufficient amount of MMP inhibitor.

Several inhibitors of the proteasome/ubiquitination system are known in the art, like for example PS-341 and MG-132 and ubiquitin ligase inhibitor that work well in cells. Likewise, there is a number of effective MMP and Tumour Necrosis Factor Converting enzyme (TACE) inhibitors, like for example, Tapi-I and Marimastat. Now the mechanism is known, it is clear for a person skilled in the art, how to select, make, or produce, functional derivatives or analogues, that have the same effect at least in kind, if not in amount on the ubiquitination process, the degradation in the proteasome or the lysosome and the cleaving of GHR on the membrane. In a more preferred embodiment, said proteasome/ubiquitination inhibitor comprises a proteasome inhibitor and/or an ubiquitination inhibitor, for example, but not limited to PS-341, or MG-132 and said MMP inhibitor comprises a hydroxamic acid-based inhibitor, like for example a Tumour Necrosis Factor Converting enzyme (TACE) (also known as ADAM17) inhibitor, for example Tapi-I or Marimastat. The increasing effect of both said inhibitors on the amount and residence of

said GHR on the cell surface increases an anabolic state which is beneficial for a patient in a cachectic or catabolic state. For signal transduction, both the GHR and growth hormone need to be present, thus the effect of both said inhibitors on the clinical results is increased by raising the level of growth hormone in said patient. Therefore, in another embodiment of the invention, said inhibitors are provided in conjunction to a growth hormone and/or a functional equivalent thereof, wherein functional equivalent of a growth hormone comprises any ligand that can exert a growth hormone like action and/or signal to the cell by binding to the GHR. Said growth hormone level can also be increased by administering substances that induce the release of natural growth hormone in the body. Therefore, in a more preferred embodiment of the invention, the growth hormone level in the body is intentionally increased, comprising administering a growth hormone releasing factor and/or a functional equivalent thereof and/or inhibiting a growth hormone release- inhibiting factor like somatostatin, wherein functional equivalent of a growth hormone releasing factor comprises any ligand that can exert a growth hormone releasing factor like action, and a functional equivalent of somatostatin comprises any ligand that can exert a somatostatin-like action. A functional derivative of a protein is defined as a protein which has been altered such that the properties of said protein are essentially the same in kind, not necessarily in amount. A derivative can be provided in many ways, for instance through conservative amino acid substitution.

A person skilled in the art is well able to generate analogous compounds of a protein. This can for instance be done through screening of a peptide library. Such an analogue has essentially the same immunogenic properties of said protein in kind, not necessarily in amount.

A proteasome/ubiquitination inhibitor and an MMP inhibitor can be combined in one composition, or they can be administered to the same patient in conjunction to each other. In conjunction herein meaning that said proteasome/ubiquitination inhibitor is used or applied before, during or after

administration of MMP inhibitor. Thus one embodiment of the invention provides a pharmaceutical composition comprising a proteasome/ubiquitination inhibitor and an MMP inhibitor for up-regulating the bio-availability of a GHR. Another embodiment of the invention provides a pharmaceutical composition comprising a proteasome/ubiquitination inhibitor and an MMP inhibitor for up-regulating the bio-availability of a GHR, wherein both the inhibitors are combined before administering to a patient. As mentioned above the combination of both inhibitors with an increase of growth hormone is even more beneficial to a patient, because the increased amounts of GHR, together with growth hormone give a stronger and longer lasting signal to the cells. A more preferred embodiment of the invention thus provides said pharmaceutical composition for administering in conjunction with growth hormone or even more preferred in conjunction with growth hormone releasing factor. In conjunction herein meaning that said composition is used or applied before, during or after hormonal treatment with growth hormone and/or growth hormone releasing factor and up-regulates or modifies the activity of said hormone. The release of growth hormone can be inhibited by substances like for example somatostatin. Inhibiting said inhibitor, i.e. inhibiting for example somatostatin results in an increased release of growth hormone. Thus the increase of growth hormone can also be achieved by administration of a somatostatin inhibitor or a functional equivalent thereof. Therefore, the invention also provides said pharmaceutical composition for administering in conjunction with a somatostatin inhibitor or a functional equivalent or analogue thereof. All substances of abovementioned pharmaceutical compositions can be combined for an optimal treatment of patients, thus the invention also provides pharmaceutical compositions in which said inhibitors and/or growth hormone, and/or growth hormone releasing factor, and/or somatostatin is combined before administering to a patient. Treating patients with cachexia or a catabolic state with said pharmaceutical compositions results in an increased anabolic state of said patients. Thus, the invention also

provides a method to use said pharmaceutical composition for the manufacture of a medicament for increasing anabolic conditions in patients suffering from a catabolic state and/or cachexia, wherein the cause of said catabolic state and/or cachexia comprises for example cancer, aids, severe burning, uremia, Cushing's syndrome, neuromuscular disorders, immobility and old age. Said medicament is also useful for the treatment of animals that are in a catabolic state. Therefore, another embodiment of the invention provides for said pharmaceutical compositions, said medicament and said methods to treat mammals suffering from a catabolic state and/or cachexia.

The invention is further explained in the following examples.

Example 1

Effect of proteasome and metalloprotease inhibitors on the GHR

Materials and methods

Cell lines and plasmids. Chinese hamster lung cells, ts20, bearing a thermolabile ubiquitin-activating enzyme E1, and E36 control cells were stably transfected with a pCB6 construct containing the full length rabbit GHR cDNA sequence. The newly established cell lines were grown at 30°C in MEM α supplemented with 10% FCS, 4.5 g/l glucose, 100 U/ml penicillin, 100 μ g/ml streptomycin and 0.45 mg/ml geneticin (van Kerkhof et al., 2002). Sixteen hours before the start of the experiment, 10 mM butyrate was added to increase the expression of the GHR (van Kerkhof et al., 2002).

Antibodies and materials. Polyclonal antibodies to the GHR cytosolic tail were raised in rabbits against fusion proteins of glutathione-S-transferase and GHR peptides consisting of amino acids 271-318 (anti-T) or 327-493 (anti-B) as described before (van Kerkhof et al., 2002). The antibody mAb5 recognising the

luminal part of the GHR was from AGEN Inc. (Parsippany, NJ). hGH was a gift from Lilly Research Labs (Indianapolis, IN). The metalloprotease inhibitors Tapi-I and GM6001, and the proteasome inhibitor MG-132 (carbobenzoxyl-L-leucyl-L-leucyl-L-leucinal) were from Calbiochem. Inhibitors were dissolved in dimethylsulfoxide (DMSO).

Ligand binding. ^{125}I -human GH was prepared using chloramine T. Cells were washed with MEM" supplemented with 20 mM Hepes pH 7.4 and 0.1% BSA and incubated with ^{125}I -GH (8 nM) for 90 minutes at 0°C. Unbound radioactivity was aspirated, the cells were washed and the radioactivity was measured after solubilisation in 1 N NaOH. Non-specific radioactivity was determined in the presence of excess unlabelled ligand and subtracted.

Cell lysis, immunoprecipitation, and western blotting. Cells (in 6-cm dishes) were lysed on ice in 1.0 mL of lysis buffer containing 1% Triton X-100, 1 mM EDTA in PBS, with 50 mM NaF, 1 mM Na_3VO_4 , 10 $\mu\text{g/ml}$ aprotinin, 10 $\mu\text{g/ml}$ leupeptin, and 1 mM PMSF. Cell lysates were subjected to SDS-polyacrylamide gel electrophoresis using a precast ready gel system (BioRad, Veenendaal, The Netherlands) and transferred to polyvinylidenedifluoride (PVDF) paper. The blots were immunostained using the polyclonal GHR antibodies anti-T or anti-B or the monoclonal antibody mAb5 followed by peroxidase conjugated protein A or rabbit anti-mouse IgG (Pierce Chemical Co.) as described previously (van Kerkhof et al. 2002), and detected by enhanced chemiluminescence (Roche Molecular Biochemicals).

Results

Effect of proteasome and metalloprotease inhibitors on the GHR.

Proteasome inhibitors inhibit uptake of the GHR both in the presence and absence of ligand (van Kerkhof et al., 2002). The ubiquitin-dependent endocytosis (UbE) motif is required in both uptake modes (Strous and Govers,

1999; van Kerkhof et al., 2002). In the expectation that proteasome inhibitors would increase the amount of mature receptor we incubated the cells with MG132 for 3h. Surprisingly, the signal was decreased, while the amount of precursor (a measure for steady state synthesis) remained constant (Fig. 1, lane 2). Our previous studies showed that, once at the cell surface, the number of GHRs is also regulated by shedding (10-20%) (van Kerkhof et al., 2002). Therefore, we used the specific TACE inhibitor Tapi-I to examine its effect on the steady state concentration. As seen in Fig. 1, lane 3, this inhibitor induces a slight increase of the amount of mature GHR while the precursor form remained unchanged. In the next experiment (lane 4) we combined the two inhibitors: the steady state amounts of mature GHR was increased considerably as compared to control cells (lane 1). Again no change in the precursor form was detectable, indicating that inhibition of the proteasome had no effect on the steady-state amount of GHR in the ER. Lane 5 shows the effect of a 3-h period of protein synthesis inhibition by cycloheximide: this control experiment confirms that GHR has a high turnover and that indeed both species of the GHR have virtually disappeared from the biosynthetic compartment as well as at the cell surface. Thus, MG132 alone accelerates the GHR shedding considerably. This is also indicated by the appearance of an extra band of 65kD in lane 2, which is only detectable with antibodies against the cytosolic tail, representing the trans membrane and cytosolic tail of the GHR after removal of the GHBP by TACE.

To quantify these results a binding study was performed using ^{125}I -GH (Fig. 2). The data show that the number of GHR at the cell surface decreased in the presence of MG132 to 50% of untreated cells, while a slight increase (35%) was detectable in the presence of a metalloprotease inhibitor. The combination of the two classes of inhibitors confirms the results of Fig. 2: an almost two-fold increase of GHR binding sites at steady state. Taken together: if the ubiquitin-proteasome system is inhibited by proteasome inhibitors, no GHR

uptake occurs, but, due to the increased activity of TACE (increasing shedding), the net effect is less GHRs available for GH signal transduction. Our data show that application of a combination of proteasome inhibitors and TACE inhibitors results in a significant increase of the number of GHR at the cell surface. To illustrate that the effect of Tapi-I on the amount of mature GHRs is due to its effect on shedding, we examined the growth medium of the cells after 150 min for the presence of GH binding protein (GHBP). Western blot analysis confirmed both the general metalloprotease inhibitor GM6001 and the more specific TACE inhibitor Tapi-I almost completely inhibited the shedding of GHBP already at 1 μ M. Hydroxamic acid-based inhibitors, which bind the essential zinc ion at the active site of the protease, were originally designed as inhibitors of zinc-dependent matrix metalloproteases (MMP). In addition, these inhibitors have been shown to inhibit protein ectodomain shedding of several different types of membrane proteins including pro-TNF α , Fas ligand, pro-transforming growth factor TGF α , 80-kDa TNF α receptor, IL-6 receptor, thyrotropin receptor, angiotensin converting enzyme, L-selectin, and β -APP, (Baumann, 2001). In this study, we used GM6001, a broad-spectrum matrix metalloprotease inhibitor to inhibit shedding, Tapi-I, an inhibitor of TACE, and MG132 to inhibit uptake. Based on our previous studies that the ubiquitin-proteasome system accounts for more than 80% of GHR disappearance from the cell surface via uptake and lysosomal degradation, we expected that MG132 activity would suffice to increase GHR at the cell surface at least two-fold. As the ubiquitin-proteasome system turns out to be a negative regulator of the MMPs, only the combination of the two inhibitors was effective in keeping the GHRs at the surface in the absence of GH. It should be noticed that the trimeric complex GH-GHR2 is resistant to MMP activity as we and others have published previously (van Kerkhof et al., 2002). Based on our data, we conclude that the combination of the two classes of drugs increases the availability of the GHR for GH approximately two-fold. Presently, prototypes of both class of inhibitors are being used in clinical trials

to relieve/cure cancer in humans e.g. in treating patients with refractory or relapsed acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia in blast phase, or myelodysplastic syndrome, and in a concomitant therapy with the potent proteasome inhibitor PS-341 and radiation in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Metalloprotease inhibitors, e.g. marimastat, are tested in many studies a.o. in patients with small cell lung cancer. As the GH-axis is a major regulator of metabolism throughout life, we use the potential of this drug combination to increase the number of GHRs at the cell surface which will induce anabolic conditions in humans suffering from catabolism and cachexia.

Legends to the Figures.

Fig. 1.

Effect of various drugs on GHR species. Cells were treated for 3 h as follows: lane 1, vehicle; lane 2, MG132 (10 μ M); lane 3, Tapi-I (10 μ M); lane 4, MG132 (10 μ M) and Tapi-I (10 μ M); lane 5, cycloheximide (0.1 mM); m, mature; p, precursor GHR. The lower band in lane 2 is the cytosolic tail, after removal of GHBP by TACE.

Fig. 2.

Quantification of receptors at the cell surface. Cells were treated as in Fig. 1 with vehicle (DMSO), cycloheximide (CH), MG132, Tapi-I, and a combination of MG132 and Tapi-I (Tapi/MG) followed by incubation with 125 I-GH on ice. The number GHRs were calculated and expressed as a percentage of untreated cells.

Fig. 3.

Effect of metalloprotease inhibitors on the release of GH binding protein. Cells grown in 12-cluster plates (0.15 mL MEM α /Hepes) were treated with increasing concentrations of the general MMP-inhibitor GM6001 or the specific TACE inhibitor Tapi-I. 15 μ L samples were taken after 150 min at 30°C and analysed by Western blotting using Mab5 antibody.

Reference List

Amit T, Hochberg Z, Yogev-Falach M, Youdim MB, Barkey RJ: Shedding of growth hormone-binding protein is inhibited by hydroxamic acid-based protease inhibitors: proposed mechanism of activation of growth hormone-binding protein secretase. *J Endocrinol* 169 (2001) 397-407.

Baumann G: Growth hormone binding protein 2001. *J Pediatr Endocrinol Metab* 14 (2001) 355-75.

Ciechanover A, Schwartz AL: Ubiquitin-mediated degradation of cellular proteins in health and disease. *Hepatology* 35 (2002) 3-6.

Hershko A, Ciechanover A, Varshavsky A: The ubiquitin system. *Nature Medicine* 6 (2000) 1073-1081.

Mitch WE, Goldberg AL: Mechanisms of disease: mechanisms of muscle wasting - the role of the ubiquitin-proteasome pathway. *N Engl J. Med* 335, (1996) 1897-1905.

Strous GJ, Govers R: The ubiquitin-proteasome system and endocytosis. *J. Cell Science* 112 (1999) 1417-1423.

Takagi K, Saito Y, Sawada J: Proteasome inhibitor enhances growth hormone-binding protein release. *Mol Cell Endocrinol* 182 (2001) 157-63.

van Kerkhof P, Smeets M, Strous GJ: The Ubiquitin-Proteasome Pathway Regulates the Availability of the GH Receptor. *Endocrinol* 143 (2002) 1243-1252.

Zhang Y, Jiang J, Black RA, Baumann G, Frank SJ: Tumor necrosis factor- α converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. *Endocrinol* 141 (2000) 4342-8.

Claims

1. A method for up-regulating the bio-availability of a cell surface receptor comprising decreasing both the uptake and/or degradation of said receptor and the extracellular cleaving of said receptor.
2. A method according to claim 1 wherein said receptor comprises a growth hormone receptor (GHR).
3. A method according to claim 1 or 2 wherein said uptake and/or degradation is decreased by a proteasome/ubiquitination inhibitor.
4. A method according to any one of claims 1-3 wherein said cleaving is decreased by a matrix metalloprotein (MMP) inhibitor.
5. A method according to any one of claims 1-4 comprising providing a proteasome/ubiquitination inhibitor in conjunction with an MMP inhibitor.
6. A method according to any one of claims 1-5 wherein said proteasome/ubiquitination inhibitor comprises a proteasome inhibitor and/or an ubiquitination inhibitor, more specifically PS-341 or MG132 or a functional derivative or analogue thereof.
7. A method according to any one of claims 1-6 wherein said MMP inhibitor comprises a hydroxamic acid-based inhibitor or a functional derivative or analogue thereof.
8. A method according to any one of claims 1-7 wherein said MMP inhibitor comprises a Tumour Necrosis Factor Converting enzyme (TACE) inhibitor or a functional derivative or analogue thereof.
9. A method according to any one of claims 1-8 wherein said MMP inhibitor comprises Tapi-I and/or Marimastat or a functional derivative or analogue thereof.
10. A method according to any of claims 1-9, wherein said inhibitors are provided in conjunction to a growth hormone and/or a functional equivalent thereof.

11. A method according to any of claims 1-10 also comprising increasing the growth hormone level in the body, comprising administering a growth hormone releasing factor and/or a functional equivalent thereof.
12. A method according to any of claims 1-11 also comprising increasing the growth hormone level in the body, comprising administering somatostatin and/or a functional equivalent thereof.
13. A pharmaceutical composition for up-regulating the bio-availability of a GHR comprising a proteasome/ubiquitination inhibitor and an MMP inhibitor.
14. A pharmaceutical composition according to claim 13 wherein said proteasome/ubiquitination inhibitor and said MMP inhibitor are combined before administering to a patient.
15. A pharmaceutical composition according to claim 13 or 14 also comprising a growth hormone and/or a functional equivalent thereof.
16. A pharmaceutical composition according to any one of claims 10-15 also comprising a growth hormone releasing factor and/or a functional equivalent thereof.
17. A pharmaceutical composition according to any one of claims 10-16 also comprising somatostatin and/or a functional equivalent thereof.
18. A pharmaceutical composition according to any one of claims 10-17, wherein said inhibitors and said growth hormone and/or said growth hormone releasing factor and/or said somatostatin and/or a functional equivalent of any of these, are combined before administering to a patient.
19. Use of a pharmaceutical composition according to any of claims 10-18 for the manufacture of a medicament for increasing anabolic conditions in human patients suffering from a catabolic state and/or cachexia.
20. Use according to claim 19, wherein the cause of said catabolic state and/or cachexia comprises a cancer, and/or an auto-immune disease, and/or an inflammatory disease.

21. Use of a pharmaceutical composition according to any of claims 13-18 for the manufacture of a medicament for increasing anabolic conditions in mammals suffering from a catabolic state and/or cachexia.




Fig. 1.




Fig. 2.




Fig. 3.

INTERNATIONAL SEARCH REPORT

Internati Application No

PCT/NL 03/00303

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/22 A61K38/55 A61P3/00 //(A61K38/55,38:22),
(A61K38/22,31:445)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, MEDLINE, EPO-Internal, WPI Data, PAJ, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VAN KERKHOF PETER ET AL: "The ubiquitin-proteasome pathway regulates the availability of the GH receptor." ENDOCRINOLOGY, vol. 143, no. 4, April 2002 (2002-04), pages 1243-1252, XP008007325 April, 2002 ISSN: 0013-7227 cited in the application	1-4,6-10
Y	the whole document -& ZHANG-Y ET AL.: "Tumor necrosis factor-alpha converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: The metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation." ENDOCRINOLOGY, vol. 141, no. 12, 2000, pages 4342-4348, XP002211275 -/--	1-21



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

19 June 2003

Date of mailing of the international search report

27/06/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lechner, 0

INTERNATIONAL SEARCH REPORT

Internal ication No

PCT/NL 03/00303

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>cited in the application abstract page 4347, left-hand column, paragraph 3 -right-hand column, paragraph 2 ---</p> <p>VAN KERKHOF P ET AL: "The ubiquitin-proteasome pathway regulates lysosomal degradation of the growth hormone receptor and its ligand." BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 29, no. 4, August 2001 (2001-08), pages 488-493, XP001022324 ISSN: 0300-5127 cited in the application abstract figure 1E page 490, right-hand column, paragraphs 2,3 ---</p>	1-21
Y	<p>ELLIOTT PETER J ET AL: "The proteasome: A new target for novel drug therapies." AMERICAN JOURNAL OF CLINICAL PATHOLOGY, vol. 116, no. 5, November 2001 (2001-11), pages 637-646, XP008007324 ISSN: 0002-9173 abstract page 638, right-hand column, paragraphs 2,3 page 639, right-hand column, paragraph 5 page 641-642 ---</p>	1-21
Y	<p>KHERADMAND FARRAH ET AL: "Shedding light on sheddases: Role in growth and development." BIOESSAYS, vol. 24, no. 1, January 2002 (2002-01), pages 8-12, XP002211276 January, 2002 ISSN: 0265-9247 the whole document -----</p>	1-21

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-21 (all partially)

Present claim 1 relates to an extremely large number of possible receptors to be upregulated. Support within the meaning of Article 6, PCT and/or disclosure within the meaning of Article 5, PCT is to be found, however, for only a very small proportion of the molecules claimed. In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Present claim 7 relates to an extremely large number of possible hydroxamic acid-based inhibitors. In fact, the claims contain so many options that a lack of clarity (and conciseness) within the meaning of Article 6, PCT arises to such an extent as to render a meaningful search of the claims impossible.

Present claims 2-21 relate to molecules defined by reference to a desirable characteristic or property, namely being inhibitors of proteasome/ubiquitination, MMPs and TACE. The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6, PCT and/or disclosure within the meaning of Article 5, PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6, PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Claims 6-21, also relate to an extremely large number of possible compounds, i.e. functional derivatives, equivalents and analogues, respectively. In fact, the claims contain so many options that a lack of clarity (and conciseness) within the meaning of Article 6, PCT arises to such an extent as to render a meaningful search of the claims impossible.

Claims 1-21 (as far as relating to an in vivo method), finally, relate to an extremely large number of ill defined pathologic conditions/diseases circumscribed by a result to be achieved and patho-physiological mechanism, respectively, i.e. up-regulating bio-availability of a receptor by decreasing both the uptake and/or degradation of said receptor and extracellular cleaving of said receptor, increasing the GH level in the body, increasing anabolic conditions in human patients suffering from a catabolic state and/or cachexia, inflammatory disease. Support within the meaning of Article 6, PCT and/or disclosure within the meaning of Article 5, PCT is to be found, however, for only a very small proportion of the pathologic conditions/diseases claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

As a consequence of the above mentioned objections, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the use of the proteasome/ubiquitination inhibitors PS431 and MG132 alone or in combination with the MMP inhibitors Tapil and Marimastat and/or GH and/or GHRF and/or somatostatin for treating cancer, AIDS, uraemia, Cushing's syndrome, cachexia and wasting (c.f. page 1, paragraph 2), respectively. In addition to the up-regulation of a GHR as defined in claim 2, the general concept of increasing the availability of surface receptors using inhibitors of the proteasome/ubiquitination and the shedding system was searched.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NL 03/00303

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-12 (as far as relating to an in vivo application) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-21 (all partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.